CircoMax Myco
Table of contents
Overview
CircoMax Myco is a veterinary vaccine used to protect pigs against two separate infections caused by porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae.
PCV2 infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).
Infection with the bacterium M. hyopneumoniae in pigs causes a disease of the airways called enzootic pneumonia. Affected pigs often have a cough and fail to thrive.
CircoMax Myco contains inactivated (killed) recombinant porcine circovirus and an inactivated strain of M. hyopneumoniae.
Authorisation details
Product details | |
---|---|
Name |
CircoMax Myco
|
Agency product number |
EMEA/V/C/005184
|
Active substance |
|
Species |
Pigs (for fattening)
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AL08
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium
|
Date of issue of marketing authorisation valid throughout the European Union |
09/12/2020
|
Contact address |
Zoetis Belgium |
Product information
09/12/2020 CircoMax Myco - EMEA/V/C/005184 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for suidae
Therapeutic indication
Active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with PCV2 infection. Protection was demonstrated against porcine circovirus types 2a, 2b and 2d.
Active immunisation of pigs against Mycoplasma hyopneumoniae to reduce the lung lesions associated with Mycoplasma hyopneumoniae infection.
Onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.
Duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.
In addition, vaccination has been shown to reduce body weight gain losses under field conditions.